This database contains 154 studies, archived under the term: "UK"
Click here to filter this large number of results.
18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias
O'Brien, J. T.,
Firbank, M. J.,
Davison, C.,
Barnett, N.,
Bamford, C.,
Donaldson, C.,
Olsen, K.,
Herholz, K.,
Williams, D.,
Lloyd, J.
Unlabelled: Brain imaging with glucose ((18)F-FDG) PET or blood flow (hexamethylpropyleneamine oxime) SPECT is widely used for the differential diagnosis of dementia, though direct comparisons to clearly establish superiority of one method have not been undertaken.; Methods: Subjects with Alzheimer disease (AD; n = 38) and dementia with Lewy bodies (DLB; n = 30) and […]
Plasma free choline, betaine and cognitive performance: the Hordaland Health Study
Nurk, Eha,
Refsum, Helga,
Bjelland, Ingvar,
Drevon, Christian A.,
Tell, Grethe S.,
Ueland, Per M.,
Vollset, Stein E.,
Engedal, Knut,
Nygaard, Harald A.,
Smith, David A.
Choline and betaine are nutrients involved in one-carbon metabolism. Choline is essential for neurodevelopment and brain function. We studied the associations between cognitive function and plasma concentrations of free choline and betaine. In a cross-sectional study, 2195 subjects (55 % women), aged 70-74 years, underwent extensive cognitive testing including the Kendrick Object Learning Test (KOLT), […]
Encouraging lifestyle behaviour change in mild cognitive impairment patients: Development of appropriate educational material
Neville, Charlotte E.,
McCourt, Hannah J.,
McKinley, Michelle C.,
Lowis, Carole,
Barrett, Suzanne L.,
McGuinness, Bernadette,
Todd, Stephen,
Lawlor, Brian,
Gibb, Matthew,
Coen, Robert F.,
Passmore, Anthony P.,
Woodside, Jayne V.
Objectives: A healthy lifestyle may help maintain cognitive function and reduce the risk of developing dementia. This study employed a focus group approach in order to gain insight into opinions of mild cognitive impairment (MCI) patients, caregivers (CG) and health professionals (HP) regarding lifestyle and its relationship with cognition. The qualitative data were used to […]
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation
Nathan, Pradeep J.,
Boardley, Rebecca,
Scott, Nicola,
Berges, Alienor,
Maruff, Paul,
Sivananthan, Tharani,
Upton, Neil,
Lowy, Martin T.,
Nestor, Peter J.,
Lai, Robert
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H₃ receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study […]
The effect of exercise on behavioural and psychological symptoms of dementia: The EVIDEM-E randomised controlled clinical trial
Lowery, David,
Cerga-Pashoja, Arlinda,
Iliffe, Steve,
Thuné-Boyle, Ingela,
Griffin, Mark,
Lee, James,
Bailey, Alex,
Bhattacharya, Rahul,
Warner, James
Objective: The objective of this study is to evaluate the effectiveness of a simple dyadic (person with dementia and their main carer) exercise regimen as a therapy for the behavioural and psychological symptoms of dementia. Method: A two arm, pragmatic, randomised, controlled, single‐blind, parallel‐group trial of a dyadic exercise regimen (individually tailored walking regimen designed […]
A phase II trial of tideglusib in Alzheimer’s disease
Lovestone, Simon,
Boadab, Mercè,
Dubois, Bruno,
Hüll, Michael,
Rinne, Juha O.,
Huppertz, Hans-Jürgen,
Calero, Miguel,
Andrés, María V.,
Gómez-Carrillo, Belén,
Leon, Teresa,
del Seri, Teodoro
Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer’s disease (AD). Objective: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. Methods: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14–26) AD patients on cholinesterase inhibitor and/or memantine treatment […]
Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial
Livingston, G.,
Barber, J.,
Rapaport, P.,
Knapp, M.,
Griffin, M.,
King, D.,
Livingston, D.,
Mummery, C.,
Walker, Z.,
Hoe, J.,
Sampson, E. L.,
Cooper, C.
Objective: To assess whether a manual based coping strategy compared with treatment as usual reduces depression and anxiety symptoms in carers of family members with dementia.; Design: Randomised, parallel group, superiority trial.; Setting: Three mental health community services and one neurological outpatient dementia service in London and Essex, UK.; Participants: 260 carers of family members […]
Memantine improves goal attainment and reduces caregiver burden in Parkinson’s disease with dementia
Objective: Memantine, an uncompetitive antagonist of N‐methyl‐D‐aspartate receptors, may have a role in managing symptoms associated with dementia in Parkinson’s disease (PDD), although its role in improving patient‐reported outcomes (PROs) has not been extensively investigated. PROs may be more sensitive than standard psychometric measures for detecting change in complex conditions such as PDD. The aim […]